Novo Nordisk Wobble Shaves 1.6 Percentage Points Off Denmark's 2025 GDP as US Exports Fall to 0.9%

Denmark's economy ministry has chopped its 2025 GDP forecast to 1.4% from an earlier 3%. The headline culprit: a wobble at Novo Nordisk (Copenhagen: NOVO-B) and weaker demand for Danish exports to the U.S. after tariff changes, the ministry said.

Public officials pointed to intensifying rivalry in the market for GLP-1 weight-loss treatments as a drag on the pharmaceutical sector. Novo Nordisk, maker of Wegovy and Ozempic, has trimmed its full-year sales and operating profit outlook twice this year and is competing head-to-head with Eli Lilly (NYSE: LLY) for market share. The company employs roughly 34,000 people in Denmark and was a big engine of last year's growth - accounting for about one-fifth of the country's employment expansion.

There are other hits to the top line. The ministry flagged a sharp slowdown in exports to the United States after a surge in late 2024, blaming tariffs for a meaningful fall in H1 shipments. Export growth for 2025 has been pared back to 0.9% from a May forecast of 4.3%.

That concentration risk matters because the Danish market is heavily export-oriented and dominated by a handful of global names. Shipping giant A.P. Moller - Maersk (Copenhagen: MAERSK-B), brewer Carlsberg (Copenhagen: CARL-B) and turbine maker Vestas (Copenhagen: VWS) are all tied to global demand cycles. When the biggest domestic success story starts to slip, it ripples through growth projections and market sentiment.

Interestingly, the ministry doesn't see the slowdown lasting. Its 2026 GDP estimate was nudged up to 2.1% from 1.4% in May, based on expectations of higher private and public spending.

For market players, the takeaway is a tighter 2025 outlook driven by one dominant pharma name and trade frictions - a reminder of how a single sector can tilt a small, open economy. The numbers to remember: 2025 GDP cut to 1.4% (from 3%), exports trimmed to 0.9% growth (from 4.3%), and 2026 forecast raised to 2.1%.